Moderna (LTS:0A45) Accounts Payable : $183 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Moderna Accounts Payable?

Moderna's Accounts Payable for the quarter that ended in Mar. 2024 was $183 Mil.

Moderna's quarterly Accounts Payable increased from Sep. 2023 ($494 Mil) to Dec. 2023 ($520 Mil) but then declined from Dec. 2023 ($520 Mil) to Mar. 2024 ($183 Mil).

Moderna's annual Accounts Payable increased from Dec. 2021 ($302 Mil) to Dec. 2022 ($487 Mil) and increased from Dec. 2022 ($487 Mil) to Dec. 2023 ($520 Mil).

Moderna Accounts Payable Historical Data

The historical data trend for Moderna's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moderna Accounts Payable Chart

Moderna Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable

Get a 7-Day Free Trial

7.09

18.00

302.00

487.00

520.00

Moderna Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable	Get a 7-Day Free Trial															389.00	310.00	494.00	520.00	183.00

Moderna Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Moderna Accounts Payable Related Terms

Thank you for viewing the detailed overview of Moderna's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Moderna (LTS:0A45) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (LTS:0A45) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

MRNA:USA MRNA:Peru MRNA:Mexico 0QFd:UK 0QF:Germany M1RN34:Brazil MRNA:Austria

Address

200 Technology Square, Cambridge, MA, USA, 02139

Website

https://www.modernatx.com

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Moderna (LTS:0A45) Headlines

No Headlines